Julie Vose, MD, MBA, Discusses Novel Treatment Options for Hematologic Malignancies

Video

Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center, discusses novel treatment options for patients with hematologic malignancies at the 2021 American Society of Clinical Oncology Annual Meeting.

At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center, about how patients have numerous novel treatment options. She highlighted how these new options can work alone or potentially as part of a combination regimen in future treatment strategies. 

Transcript:

The interesting aspects are looking at not only new drugs, new monoclonal antibodies, new CAR T-cells, [or] new bispecific antibodies. Looking at all these different modalities that can be utilized for all different types of hematologic malignancies, either alone or potentially in the future, combined together [is interesting]. We are going to have so many potential treatments that we will be able to [utilize to] help more patients and be able to get these new novel therapies to many more people.

Related Videos
Naveen Pemmaraju, MD, with the Oncology Brothers
Naveen Pemmaraju, MD, with the Oncology Brothers
Naveen Pemmaraju, MD, with the Oncology Brothers
Naveen Pemmaraju, MD, with the Oncology Brothers
Naveen Pemmaraju, MD, with the Oncology Brothers
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Related Content